At a Glance
| Item | Detail |
|---|---|
| CDL / PMB Status | Chronic Disease List (CDL) condition |
| ICD-10 Codes | E03.0–E03.9 |
| SA Prevalence | ~3% (~1.5–1.8 million people) |
| Annual Cost (managed) | R1,200–R3,500 |
| Annual Cost (specialist-managed) | R3,500–R4,800 |
| Biologic Risk | No |
| Gap Cover Relevance | Low |
What is Hypothyroidism?
Hypothyroidism occurs when the thyroid gland produces insufficient thyroid hormone (thyroxine — T4, and tri-iodothyronine — T3). Thyroid hormones regulate metabolism throughout the body — when levels fall, virtually every organ system slows.
Symptoms are non-specific and often develop gradually: fatigue, weight gain, cold intolerance, constipation, dry skin, hair loss, depression, brain fog, and menstrual irregularities in women. Because these symptoms are common and overlap with many other conditions, hypothyroidism is frequently under-diagnosed or misattributed to other causes.
The most common cause in South Africa is Hashimoto's thyroiditis — an autoimmune condition where the immune system attacks the thyroid gland. Other causes include post-radioactive iodine therapy (for previous hyperthyroidism), thyroid surgery, and iodine deficiency (now rare in SA due to iodised salt, but historically relevant in Karoo communities).
Hypothyroidism is a Chronic Disease List (CDL) condition. Approximately 1.5–1.8 million South Africans are affected, with women 5–10 times more commonly affected than men.
Subclinical vs. Overt Hypothyroidism
Overt hypothyroidism: TSH elevated (> 10 mIU/L) with low free T4. Symptoms typically present. Treatment is indicated.
Subclinical hypothyroidism: TSH elevated (4–10 mIU/L) with normal free T4. Often asymptomatic. Treatment decision is nuanced — depends on severity of TSH elevation, presence of anti-TPO antibodies, symptoms, age, and cardiovascular risk. Not all subclinical hypothyroidism requires levothyroxine.
How is Hypothyroidism Treated?
Levothyroxine (synthetic T4) is the standard, sole treatment for hypothyroidism in the vast majority of patients. It is one of the most commonly prescribed medications in South Africa and globally.
Key points about levothyroxine: - Taken once daily, on an empty stomach, 30–60 minutes before breakfast (or at bedtime, away from evening snacks) - Avoid calcium, iron, coffee, or antacids within 4 hours — they impair absorption significantly - Starting dose depends on age and cardiovascular status — typically 25–50mcg in elderly or cardiac patients, 50–100mcg in younger adults - Dose is titrated based on TSH levels every 6–8 weeks until stable - Once stable: TSH check every 6–12 months
Combination T4/T3 therapy (liothyronine + levothyroxine): Occasionally used in specialist practice for patients who remain symptomatic on T4 alone (hypothesised poor T4→T3 converter). Evidence is mixed; not standard first-line. More expensive and requires more frequent monitoring.
Medication Costs (2025/2026 — Prices Estimated; SAHPRA SEP Verification Pending)
| Medication | Class | Monthly Cost | Annual Cost |
|---|---|---|---|
| Levothyroxine 100mcg (Euthyrox / generic) | Definitive replacement | ~R70 | ~R840 |
| Levothyroxine 50mcg (generic) | Lower-dose replacement | ~R55 | ~R660 |
| Liothyronine T3 (specialist use) | Combination therapy | ~R400 | ~R4,800 |
Levothyroxine is one of the least expensive chronic medications in the CDL set. Generic options are well-established and bioequivalent.
Annual Cost Breakdown
| Category | Low Estimate | High Estimate |
|---|---|---|
| GP visits (2 per year) | R1,600 | R1,600 |
| Endocrinologist (1 visit per year) | R1,200 | R2,500 |
| Levothyroxine (monthly) | R660 | R840 |
| Blood tests (TSH ×2; anti-TPO initial; lipid panel) | R600 | R1,200 |
| Hospital (myxoedema coma — very rare) | R0 | R35,000 |
| Total estimated annual cost | ~R4,060 | ~R6,140 |
Medical Aid Coverage
Hypothyroidism is a CDL condition. Registered open medical aid schemes must fund: - Levothyroxine at CDL formulary level — this is universally available and inexpensive - GP and endocrinologist consultations - TSH and free T4 monitoring bloods - Anti-TPO antibody testing (initial diagnosis)
Levothyroxine is on every CDL formulary without exception. It is one of the simplest CDL conditions to manage from a scheme perspective — no biologic, no exceptional needs process, no formulary gaps.
Specialist shortfall: An endocrinologist appointment may exceed scheme rate — the shortfall is the main gap cover use case.
Gap Cover Relevance
Low. Levothyroxine is inexpensive and covered. The annual cost of managing hypothyroidism is among the lowest in the CDL set (R4,000–R6,000/year). Gap cover is not a material consideration for hypothyroidism specifically. An endocrinologist shortfall (~R600–R1,200 per visit) is the only relevant scenario.
Importantly: hypothyroidism significantly increases cardiovascular disease risk if untreated or inadequately managed — including coronary artery disease and cardiac failure, both of which carry much higher gap cover relevance. The advisory for hypothyroidism should account for likely future cardiovascular conditions when assessing scheme and gap cover needs.
Key Considerations for Plan Selection
- Hypothyroidism alone does NOT drive scheme or plan selection. Levothyroxine is universally covered and costs under R900/year.
- Plan for cardiovascular comorbidity. Hypothyroidism elevates LDL cholesterol and cardiovascular risk. Scheme selection should account for eventual hyperlipidaemia and coronary artery disease management.
- TSH monitoring: Ensure your plan's blood test benefit covers at least 2 TSH tests per year. Entry-level plans sometimes restrict this.
- Pregnancy planning: Hypothyroidism must be optimally controlled before and during pregnancy. Antenatal scheme benefits and endocrinology access matter.
Sources
- SA Thyroid Association — Hypothyroidism Management Guidelines
- CMS PMB Regulation 8 — CDL: Hypothyroidism
- Jonklaas J et al. Guidelines for the Treatment of Hypothyroidism. Thyroid, 2014.
- SAHPRA SEP database — prices estimated; verification pending.
To see what your own plan pays, check your cover with AURA →
This page is general information about medical schemes. It is not medical advice: speak to a healthcare professional about your own treatment. Medical aid and gap cover advice is given by Eldon de Waal, a Supervised Representative of Approach Administration (FSP 23579).